Sustainable COVID-19 Vaccination
for Long-term Vaccine Immunity and effectiveness
As the COVID-19 pandemic continues, new variants of the SARS-CoV-2 virus are emerging, making it harder to control the virus. These variants can escape immunity provided by current vaccines, and immunity can weaken over time.
The SOLVE project is here to tackle these challenges by exploring new vaccine technologies and understanding how to create longer-lasting immunity.
Objectives
SOLVE aims to
Design new vaccines
Use cutting-edge approaches to create vaccines that target key mutations in the virus.
Evaluate immune responses
Compare four different vaccine platforms to find the most effective and long-lasting immune protection.
Test in human trials
Validate findings through an experimental medicine trial (EMT) to study immune responses in volunteers.
Study long-lasting immunity
Understand the mechanisms that lead to durable immune responses.
Integrate data science
Analyze data from trials and large population studies to predict and improve immunity.
Engage with the public
Investigate public perceptions to ensure vaccines are accepted and widely used.
Key Points
Advanced vaccine platforms
including mRNA, nanoparticles, MVA vector, and dendritic cell targeting.
A focus on variants
with key mutations to ensure broad and lasting protection.
Collaborative work
between 8 leading institutions, sharing insights rapidly to address urgent needs.
Key Numbers
14.2M€
Funding, including 8.87M€ from EU and 5.33 from SERI
5 years
From January 2024 to December 2028
6
Countries
13
Academics and private partners